During the past decade, Saga-Ken Medical Centre Koseikan conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 6 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 6 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Saga-Ken Medical Centre Koseikan" #1 sponsor was "Eli Lilly and Company" with 4 trials, followed by "Galapagos NV" with 3 trials sponsored, "Pfizer" with 3 trials sponsored, "Amgen" with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Saga-Ken Medical Centre Koseikan" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "Japan Clinical Research Support Unit(J-CRSU)" with 1 trials as a collaborator and "NPO International TRI Network" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Saga-Ken Medical Centre Koseikan" are "Ulcerative Colitis" (5 trials), "Crohn's Disease" (3 trials), "Acute Myocardial Infarction" (1 trials), "Asthma" (1 trials) and "Atherosclerotic Cardiovascular Disease" (1 trials). Many other conditions were trialed in "Saga-Ken Medical Centre Koseikan" in a lesser frequency.

Most popular intervention types in "Saga-Ken Medical Centre Koseikan" are "Drug" (17 trials), "Other" (4 trials), "Procedure" (2 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Filgotinib" (4 trials), "Mirikizumab" (3 trials), "Finerenone (BAY94-8862)" (2 trials) and "AMG 510" (1 trials). Other intervention names were less common.

The vast majority of trials in "Saga-Ken Medical Centre Koseikan" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Saga-Ken Medical Centre Koseikan". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 12 completed trials in Saga-Ken Medical Centre Koseikan, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Saga-Ken Medical Centre Koseikan, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".